Y-Intercept (HK)’s ARS Pharmaceuticals SPRY Stock Holding History

Y-Intercept (HK)’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-15,924	Closed	-$128K	–	2141
2026 Q1	$128K	Buy	+15,924	New	+$153K	﹤0.01%	1458

Other funds holding SPRY

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $330M AUM 27.75% 1-Year Est. Return

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

CX Institutional Auburn, Indiana $3.46B AUM 21.89% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Y-Intercept (HK)'s SPRY Position: Q2 2026 in Review

Y-Intercept (HK) sold out of ARS Pharmaceuticals (SPRY) in Q2 2026, closing a stake of 15,924 shares — an estimated $128K sold.

Y-Intercept (HK) first reported a position in SPRY in Q1 2026 and held it in 1 quarter. The position peaked at $128K in Q1 2026. 8 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

Y-Intercept (HK) reported no remaining ARS Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Y-Intercept (HK) sold 15,924 ARS Pharmaceuticals shares in Q2 2026, an estimated $128K.
Y-Intercept (HK) first reported a position in ARS Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Y-Intercept (HK)'s ARS Pharmaceuticals position peaked at $128K in Q1 2026.
8 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.